Related Experiment Video
Updated: Aug 1, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Apoptotic markers for primary brain tumor prognosis
A E Konstantinidou1, P Korkolopoulou, E Patsouris
1Department of Pathology, Faculty of Medicine, National Capodistrian University of Athens, 28, Narkisson street, Halandri, Athens, 152 33, Greece. ankon@med.uoa.gr
Journal of Neuro-Oncology
|June 1, 2005
Summary
Apoptosis and p53 alterations may predict poor outcomes in brain tumors, but bcl-2 expression lacks predictive value. Further research is needed to clarify the role of other apoptotic markers in treatment decisions.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Molecular insights into brain tumor pathogenesis are advancing.
- The clinical utility of apoptotic markers for predicting patient outcomes and treatment response remains unclear.
Purpose of the Study:
- To review the prognostic significance of apoptosis-related molecules in brain tumors.
- To evaluate established prognostic variables against molecular markers.
Main Methods:
- Review of existing literature on apoptosis and related molecular markers (bcl-2, bax, fas/fasL, survivin, p53) in brain tumors.
- Analysis of baseline apoptosis incidence and its correlation with prognosis.
Main Results:
- Increased apoptosis and p53 genetic alterations are associated with adverse prognostic outcomes in central nervous system neoplasms.
- bcl-2 expression shows no predictive value in primary brain tumors.
- Prognostic significance of other apoptosis-related molecules is controversial or limited.
Conclusions:
- Current evidence suggests increased apoptosis and p53 alterations as adverse prognosticators.
- bcl-2 lacks predictive value for primary brain tumors.
- Large prospective trials are necessary to validate molecular markers for personalized brain tumor treatment.
